Article ; Online: Adjuvant Chemotherapy With UFT/LV
2024 Volume 44, Issue 2, Page(s) 805–814
Abstract: Background/aim: Uracil-tegafur+leucovorin (UFT/LV), an oral adjuvant therapy for stage II/III colorectal cancer, is non-inferior to standard weekly fluorouracil and folinate. Although polysaccharide K (PSK) has been evaluated as a postoperative adjuvant ...
Abstract | Background/aim: Uracil-tegafur+leucovorin (UFT/LV), an oral adjuvant therapy for stage II/III colorectal cancer, is non-inferior to standard weekly fluorouracil and folinate. Although polysaccharide K (PSK) has been evaluated as a postoperative adjuvant colorectal cancer drug, its efficacy remains unclear. This randomized phase II trial compared UFT/LV+PSK with UFT/LV as adjuvant chemotherapy. Patients and methods: Between April 2011 and August 2016, 186 patients who underwent radical resection randomly received 6 months of UFT/LV (Group A: 300 mg/m Results: Groups A, B, and C consisted of 37, 75, and 74 patients, of which treatment was completed by 33 (89.2%), 63 (84.9%), and 53 (70.4%) patients, respectively (p=0.0279). Adverse event incidence for all grades were 59.5%, 52.1%, and 59.2%, and for grade ≥3 were 13.5%, 9.6%, and 9.9%, respectively. The 3-year disease-free survival rates were 72.5%, 82.2%, and 74.2%, respectively, with no significant differences. The preoperative lymphocyte ratio did not significantly differ between groups. Conclusion: UFT/LV+PSK is comparable to UFT/LV therapy in terms of prognostic efficacy and reduced adverse effects. Thus, UFT/LV+PSK is a useful adjuvant chemotherapy option for patients with high-risk stage II/III colorectal cancer. |
---|---|
MeSH term(s) | Humans ; Administration, Oral ; Chemotherapy, Adjuvant/adverse effects ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Leucovorin/therapeutic use ; Levamisole/analogs & derivatives ; Neoplasm Staging ; Tegafur/therapeutic use ; Uracil/therapeutic use |
Chemical Substances | Leucovorin (Q573I9DVLP) ; Levamisole (2880D3468G) ; Tegafur (1548R74NSZ) ; Uracil (56HH86ZVCT) |
Language | English |
Publishing date | 2024-02-01 |
Publishing country | Greece |
Document type | Clinical Trial, Phase II ; Randomized Controlled Trial ; Journal Article |
ZDB-ID | 604549-2 |
ISSN | 1791-7530 ; 0250-7005 |
ISSN (online) | 1791-7530 |
ISSN | 0250-7005 |
DOI | 10.21873/anticanres.16872 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1642: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.